Clinical Value of Pharmacokinetic Monitoring of Serum Paclitaxel Concentration in Paclitaxel-based Chemotherapy on Patients with Ovarian Cancer

YU Jing; ZHANG Huifeng; LEI Dandsheng

doi:10.3971/j.issn.1000-8578.2017.04.006

Cancer Research on Prevention and Treatment > 2017 > 44(4): 268-271. > DOI: 10.3971/j.issn.1000-8578.2017.04.006

YU Jing, ZHANG Huifeng, LEI Dandsheng. Clinical Value of Pharmacokinetic Monitoring of Serum Paclitaxel Concentration in Paclitaxel-based Chemotherapy on Patients with Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2017, 44(4): 268-271. DOI: 10.3971/j.issn.1000-8578.2017.04.006

Citation:

PDF (1582 KB)

Clinical Value of Pharmacokinetic Monitoring of Serum Paclitaxel Concentration in Paclitaxel-based Chemotherapy on Patients with Ovarian Cancer

1.
Department of Laboratory, Hubei Cancer Hospital, Wuhan 430079, China
2.
Depatment of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan 430079, China

More Information

Corresponding author:
LEI Dansheng E-mail:18971579828@189.cn
Received Date: July 12, 2016
Revised Date: November 03, 2016
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the relationship between plasma concentration of paclitaxel (PTX) and the efficacy as well as toxic and side effects in the patients with ovarian cancer.
Methods
Seventy-five patients with ovarian cancer accepted PT (paclitaxel+carboplatin) chemotherapy regimen as their first line treatment. The blood samples were taken twice at (24±6) h after continuous infusion of paclitaxel in each cycle and the plasma concentration of paclitaxel was detected by latex immuno-turdidimetry. The patients were randomly assigned into three groups according to the average plasma concentration of paclitaxel: group 1 (plasma concentration paclitaxel≤25h), group 2(26-30h) and group 3(≥31h). The relationship between the drug plasma concentration, therapeutic efficacy and adverse reactions in different paclitaxel plasma concentration was analyzed retrospectively.
Results
The average plasma concentrations of paclitaxel of the three groups were (22.54±2.04) h, (28.62±1.87) h, 33.01±2.84) h, respectively (P < 0.05). The incidence and extent of adverse reactions were significantly higher and stronger with the increasing plasma concentration of paclitaxel. The therapeutic efficacy of group 2 (26-30) h was 31.25% which was better than that (20%) of group 1 (≤25h) (P=0.02), but had no significant difference with that (33.33%) of group 3 (≥31h) (P=0.96).
Conclusion
The ovarian cancer patients treated with paclitaxel-based chemotherapy with an average plasma concentration of paclitaxel between 26-30h have a higher curative effect and lower toxic side effect.
- Ovarian cancer,
- Paclitaxel,
- Plasma concentration,
- Latex immuno-turdidimetry

FullText(HTML)

References (10)

References

[1]	刘晋雯.紫杉醇联合顺铂、卡铂周疗治疗卵巢癌疗效及安全评价[J].中国保健营养 (中旬刊), 2012, 6(6): 326. http://www.cnki.com.cn/Article/CJFDTOTAL-NMYZ201503034.htm Liu JW. The curative effect and safety evaluation of Paclitaxel combined Cisplatin or Carboplatin in weekly chemotherapy on ovarian cancer[J]. Zhongguo Bao Jian Yin Yang (Zhong Xun Kan), 2012, 6(6): 326. http://www.cnki.com.cn/Article/CJFDTOTAL-NMYZ201503034.htm
[2]	Hendrikx JJ, Hillebrand MJ, Thijssen B, et al. A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2011, 879(28): 2984-90. doi: 10.1016/j.jchromb.2011.08.034
[3]	董滨华, 孙蓬明, 宋一一, 等.高效液相色谱法测定卵巢癌患者血浆中紫杉醇浓度的研究[J].国际妇产科学杂志, 2013, 40(4): 372-4, 385. Dong BH, Sun PM, Song YY, et al. Determination of Paclitaxel in Ovarian Neoplasm Patients' Plasma by HPLC[J]. Guo Ji Fu Chan Ke Xue Za Zhi, 2013, 40(4): 372-4, 385.
[4]	叶怀庄, 方维佳, 徐农.高效液相色谱法在肿瘤化疗患者紫杉醇血药浓度检测中的应用[J].中华检验医学杂志, 2009, 32(2): 198-200. http://cdmd.cnki.com.cn/Article/CDMD-10570-1011304580.htm Ye HZ, Fang WJ, Xu N. Determination of chemotherapy drug in cancer patients' plasma by High performance liquid chromatography (HPLC)[J]. Zhonghua Jian Yan Yi Xue Za Zhi, 2009, 32(2): 198-200. http://cdmd.cnki.com.cn/Article/CDMD-10570-1011304580.htm
[5]	蔡讯, 薛鹏, 宋卫峰, 等.氟尿嘧啶血药浓度监测在进一步提高晚期结直肠癌以氟尿嘧啶为基础的化疗疗效中的作用[J].中华肿瘤杂志, 2012, 34(1): 39-43. http://www.cnki.com.cn/Article/CJFDTOTAL-ZZLL201110011.htm Cai X, Xue P, Song WF, et al. Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy[J]. Zhonghua Zhong Liu Za Zhi, 2012, 34(1): 39-43. http://www.cnki.com.cn/Article/CJFDTOTAL-ZZLL201110011.htm
[6]	Wang N, He T, Shen Y, et al. Paclitaxel and Tacrolimus Coencapsulated Polymeric Micelles That Enhance the Therapeutic Effect of Drug-Resistant Ovarian Cancer[J]. ACS Appl Mater Interfaces, 2016, 8(7): 4368-77. doi: 10.1021/acsami.5b09340
[7]	邹厚文, 罗会俊, 余瑛, 等.紫杉醇联合顺铂的两种给药方法治疗晚期卵巢癌疗效的比较[J].江西医药, 2014, 49(3): 232-4. http://www.cnki.com.cn/Article/CJFDTOTAL-JXYY201403023.htm Zou HW, Luo HJ, Yu Y, et al. The curative effect comparison of Paclitaxel combined Cisplatin in two administration modes on advanced ovarian cancer[J]. Jiangxi Yi Yao, 2014, 49(3): 232-4. http://www.cnki.com.cn/Article/CJFDTOTAL-JXYY201403023.htm
[8]	Wang B, Li S, Meng X, et al. Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells[J]. Tumor Biol, 2015, 36(8): 6433-43. doi: 10.1007/s13277-015-3333-2
[9]	杨建伟, 苏颖, 陈增, 等. CYP3A4基因多态性与晚期胃癌患者接受紫杉醇/奥沙利铂多线化疗、化疗周期数及不良反应的相关性[J].国际病理科学与临床杂志, 2014, 34(1): 22-8. http://www.cnki.com.cn/Article/CJFDTOTAL-WYSB201401005.htm Yang JW, Su Y, Chen Z, et al. Correlation between gene polymorphisms of CYP3A4 and multi-line chemotherapy, cycles of chemotherapy or adverse reactions in gastric cancer patients received therapy of paclitaxel and/or oxaliplatin combination regimens[J]. Guo Ji Bing Li Ke Xue Yu Lin Chuang Za Zhi, 2014, 34(1): 22-8. http://www.cnki.com.cn/Article/CJFDTOTAL-WYSB201401005.htm
[10]	杨建伟, 陈增, 苏颖, 等.胃癌细胞色素氧化酶CYP3A4基因多态性与含紫杉醇方案化疗敏感性的研究[J].临床肿瘤学杂志, 2014, 19(1): 23-8. http://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201401005.htm Yang JW, Chen Z, Su Y, et al. Trial of the correlation between cytochrome oxidase CYP3A4 with the susceptibility of paclitaxel-based regimen for advanced gastric cancer[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2014, 19(1): 23-8. http://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201401005.htm

Cited By

Cited by

Periodical cited type(5)

1.	于小梅，李晶晶，贾波. 输液港导管形成纤维蛋白鞘的不良影响及干预措施的研究进展. 当代护士(下旬刊). 2025(04): 25-29 .
2.	孙涛，罗和国. 超声引导下腋静脉穿刺置管的研究进展. 国际麻醉学与复苏杂志. 2025(04): 414-418 .
3.	金光鑫，张芳琴，王雅雯，郭艳，仇晓霞，张学彬. 超声联合DSA引导下经上臂静脉输液港植入术在恶性肿瘤化疗患者中的临床应用研究. 介入放射学杂志. 2024(07): 733-737 .
4.	程巧琳，陈金华，施晓琳，闵伟. 肌骨超声在恶性肿瘤患者行静脉输液港植入术及术后监测中的应用. 海南医学. 2024(15): 2210-2213 .
5.	田竹. 不同导管尖端定位法在静脉输液港置入中的应用研究. 循证护理. 2024(17): 3104-3108 .

Other cited types(1)

Get Citation

PDF

XML

Article views (2733) PDF downloads (842) Cited by(6)

Turn off MathJax

Article Contents

Abstract

References

Clinical Value of Pharmacokinetic Monitoring of Serum Paclitaxel Concentration in Paclitaxel-based Chemotherapy on Patients with Ovarian Cancer